PDE9A and cancer: Next, we had scrutinized promoter DNA methylation status through the UALCAN database, where promoter methylation of PDE9A in COAD was attenuated than normal tissues based on sample types, individual cancer stages, patient race, patient gender, patient age, patient weight, tumor histology, and T53 mutation status (Fig. 6).